InnovFin Infectious Diseases
The InnovFin Infectious Diseases Finance Facility (IDFF) provides financial products ranging from standard debt to equity-type financing for amounts typically between EUR 7.5 million and EUR 75 million, to innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases.
Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement.
The product is being made available directly through the European Investment Bank.
To be eligible for InnovFin Infectious Diseases Finance Facility (IDFF) funding, counterparties must comply with the following criteria:
The promoter should be a large pharmaceutical company, a mid-cap or a small and medium-sized enterprise (SME), a research institute/organisation, a university, a non-profit entity or a special-purpose vehicle (SPV). Promoters, sponsors and/or operators must be willing to substantially co-fund the project.
How to apply
Find out on this page how you can benefit from the InnovFin Infectious Diseases Finance Facility.
Companies developing new cancer treatments have a hard time raising the money to carry out their research, so the European Investment Bank finances them.
Three European start-ups are developing automated molecular diagnostics tests that slash the time it takes to detect and treat serious gastro-intestinal and respiratory diseases for patients admitted in emergency departments and intensive care units.